JSPR NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Jasper Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.63 USD
-8.5% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -34.6% below the Trend Line and sits at 11.1% of its 52-week range. The latest completed week returned -8.5%, after a 47.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 35 out of 100
Latest Close 0.63 USD 31 Jul 2026
1W Return -8.5% latest completed week
4W Return 47.1% short-term follow-through
12W Return -32.0% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -8.5% Latest completed week; four-week move 47.1%. Indicator stack 0/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 52/100 conviction; expected move 317.5%. News sentiment 52/100 58 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -34.6% below the Trend Line and sits at 11.1% of its 52-week range. The latest completed week returned -8.5%, after a 47.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 47.1% over four weeks, -32.0% over 12 weeks, and -78.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-8.5%
4W47.1%
12W-32.0%
26W-57.4%
52W-78.1%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.24Latest activity-pressure read.
Pressure change635.7%Four-week change in activity pressure.
Leadership-62.83Latest relative-leadership reading.
RS change20.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 58% Model confidence 55%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

JSPR shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 317.5%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move317.5%
Put/call volume0.00
Pressure100
Speculation0
Volatility96
Trend agreement0
Open options detail
Insider activity3 / 0

3 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment52/100

Weighted news tone is neutral across 58 relevant articles.

9 positive · 43 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move317.5%Nearest-chain priced movement where available.
52-week drawdown-79.9%Distance below the 52-week high.
13-week volatility24.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2615 weeks finished lower.
Best week+52.7%Week of 17 Jul.
Worst week-40.6%Week of 5 Jun.
Latest week-8.5%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains1
Flat weeks1
Modest losses2
Sharp losses13
Recent vol24.4%13-week weekly-return volatility.
Base vol16.1%52-week weekly-return volatility.
Up/down split21/30Count of positive and negative weeks in the 52-week window.
Average skew12.1% / -11.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis25/100

Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 0/12.

Activity pressure 0.07; No reversal markers Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

JSPR shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 317.5%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 317.5% Sentiment52/100

Weighted news tone is neutral across 58 relevant articles.

Jasper Therapeutics (Nasdaq: JSPR) outlines $30M CVR tied to briquilimab Insiders3 / 0

3 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.63 USD-8.5%0.96 USD9.62 USD1.24-62.832.3MOff
24 Jul 20260.69 USD-22.2%1.00 USD9.71 USD0.93-60.496.7MOff
17 Jul 20260.89 USD52.7%1.04 USD9.81 USD0.59-51.6952.0MOff
10 Jul 20260.58 USD35.3%1.07 USD9.90 USD0.07-70.683.2MOff
3 Jul 20260.43 USD25.6%1.11 USD9.98 USD-0.23-78.771.8MOff
26 Jun 20260.34 USD-24.7%1.15 USD10.07 USD-0.21-84.204.3MOff
19 Jun 20260.45 USD-1.0%1.20 USD10.15 USD-0.07-81.091.3MOff
12 Jun 20260.46 USD-7.1%1.25 USD10.23 USD0.20-81.411.7MOff
5 Jun 20260.49 USD-40.6%1.29 USD10.32 USD0.39-80.618.4MOff
29 May 20260.83 USD-8.2%1.33 USD10.42 USD0.47-70.53915.8KOff
22 May 20260.90 USD6.2%1.38 USD10.51 USD0.41-68.481.2MOff
15 May 20260.85 USD-8.2%1.43 USD10.61 USD0.21-71.101.5MOff
8 May 20260.93 USD-0.4%1.48 USD10.72 USD0.22-69.77966.8KOff
1 May 20260.93 USD11.0%1.53 USD10.81 USD0.08-69.081.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.